Table 3 provides data for rates of adverse events (other than incident diabetes) and measured laboratory values in the JUPITER trial comparing rosuvastatin with placebo in participants with and without one or more major diabetes risk factor. Participants with and without diabetes risk factors had similar non-diabetes adverse event rates attributable to rosuvastatin. Furthermore, in those with and without diabetes risk factors, measured HbA1c at 24 months increased by 0·1% in those allocated rosuvastatin (both p values 0·001). Of interest, measured fasting glucose concentrations were not significantly